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INTRODUCTION
Absolute bioavailability is an important parameter related to the pharmacological efficacy of orally administered drugs, and prediction of oral bioavailability is a key aspect of new drug development. Monkeys are often used in preclinical studies as non-human primates because of their genetic similarity to humans. However, the pharmacokinetic properties of drugs in monkeys are not always similar to those in humans. In particular, monkeys tend to exhibit lower bioavailability than humans (Sietsema, 1989; Chiou and Buehler, 2002; Ward et al., 2005) , and it is difficult to predict the oral bioavailability in human from data obtained in monkeys.
Since absolute oral bioavailability is affected by first-pass metabolism and/or excretion in both small intestine and liver, species difference in each process should be carefully examined to understand the factors affecting bioavailability. Chiou and Buehler (2002) showed, by analyzing literature data, including fraction of dose absorbed (Fa) and absolute bioavailability, that monkeys have similar intestinal drug absorption, but larger hepatic (nonrenal) clearance of 43 drugs compared with humans. However, the hepatic blood flow rate in monkeys is larger than that in humans (Davies and Morris, 1993) , so that the ratio of hepatic clearance to hepatic blood flow rate is not very different between humans and monkeys (Ward and Smith, 2004) , and therefore the hepatic availability (Fh) may be similar in monkeys and humans. Thus, intestinal first-pass metabolism must be considered as a candidate mechanism to account This article has not been copyedited and formatted. The final version may differ from this version. for the poor oral bioavailability in monkeys.
In contrast to Fa and Fh, there have been few systematic studies of the extent of intestinal metabolism, which directly affects intestinal availability (Fg) following oral administration. Recently, several researchers have pointed out the importance of intestinal metabolism in oral bioavailability, suggesting that it may be a defense mechanism to block passage of xenobiotics across the small intestine. Intestinal expression of CYP3A, a species of cytochrome P450, has been reported in rats (Kolars et al., 1992a; Li et al., 2002; Aiba et al., 2005) , monkeys (Hashizume et al., 2001 ) and humans (Kolars et al., 1992b; Paine et al., 1997; Zhang et al., 1999) . Interplay between CYP3A and an efflux transporter P-glycoprotein (P-gp), the substrate specificities of which partially overlap, has been proposed to be involved in determining the efficiency of intestinal first-pass removal (Watkins, 1997; Benet et al., 2004) .
Midazolam, a short-acting benzodiazepine central nervous system depressant, is a typical substrate of CYP3A, its oral bioavailability being 24 -46% in humans (Sakuda et al., 2006) . In humans, Fa•Fg and Fh were estimated to be 57 and 56%, respectively (Thummel et al., 1996) , indicating that bioavailability of midazolam is affected by both intestinal and hepatic first-pass effects.
Intraduodenally administered midazolam was rapidly absorbed with a Tmax of 15 -30 min, suggesting that midazolam is highly permeable and is mostly absorbed in the upper part of the intestine, where CYP3A expression is higher than in other regions of the small intestine (Paine et al., 1996; Paine et al., 1997) .
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Unlike humans, cynomolgus monkeys show minimal bioavailability of midazolam (about 2 -6%), though Fh was not small (~66%, (Kanazu et al., 2004; Sakuda et al., 2006) . Interestingly, Sakuda et al. (2006) recently showed that midazolam is completely absorbed by intestinal tissue in cynomolgus monkey, implying that intestinal metabolism may have a crucial role in the low bioavailability of midazolam (Sakuda et al., 2006) . In rats, on the other hand, bioavailability of midazolam after oral administration and administration into a jejunal loop was only 4.6 and 12%, respectively, but intestinal first-pass removal was at most 25% (Lau et al., 1996; Higashikawa et al., 1999) , suggesting that intestinal metabolism play a relatively minor role in rats, compared with monkeys.
In the present study, we aimed to clarify the nature of the species difference in oral bioavailability of midazolam between monkeys and rats, focusing on the intestinal first-pass. As regards membrane transport in the small intestine, several transporters have been suggested to contribute to drug absorption (Tsuji and Tamai, 1996; Katsura and Inui, 2003; Daniel, 2004; Sai and Tsuji, 2004) , and in particular, P-gp is involved in regulation of the intestinal permeation of various xenobiotics (Terao et al., 1996) . Midazolam shows high membrane permeability and is categorized as BCS class I (Wu and Benet, 2005) .
It is believed to be absorbed via passive diffusion, but not transported by P-gp (Benet and Cummins, 2001; Polli et al., 2001 ). On the other hand, another report has suggested that midazolam is a highly permeable P-gp substrate (Tolle-Sander et al., 2003) . Therefore, involvement of P-gp in the absorption of This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 30, 2007 as DOI: 10.1124 at ASPET Journals on June 22, 2017 dmd.aspetjournals.org Downloaded from midazolam remains controversial. To establish whether an efflux transporter is involved in the intestinal midazolam absorption in monkeys and rats, we evaluated midazolam transport in both apical-to-basal and basal-to-apical directions in various regions of the intestine, using an Ussing-type chamber system.
Pharmacokinetic properties of midazolam in monkeys, dogs and rats
Midazolam was dissolved in a mixture of dimethylacetamide and saline (1:1, v/v) for intravenous bolus injections at a dose of 0.1 mg/mL/kg for rats, and 0.1 mg/0.2 mL/kg for monkeys and dogs. Intravenous bolus injection was conducted without cannulation into the saphenous vein, cephalic vein and femoral vein in monkeys, dogs and rats, respectively. Midazolam was suspended in 0.5% methylcellulose solution for oral administration at a dose of 1 mg/5 mL/kg for rats, and 1 mg/2 mL/kg for monkeys and dogs. Oral administration to rats was done by gavage. Blood samples were collected at 5, 10, 15, and 30 min, and 1, 2, 4, 8, and 24 hr after intravenous administration and at 15 and 30 min, and 1, 2, 4, 8, and 24 hr after oral administration in monkeys, dogs and rats.
Transport experiment in Ussing-type chamber
Intestinal absorption mechanism of midazolam was addressed by Ussing-type chamber method, and the scheme of the apparatus was briefly described in Fig. 1A . Segments of upper, middle and lower small intestine isolated from monkeys and rats were used for the Ussing-type chamber study.
The portion approximately 15 and 4 cm from the pylorus was used as the upper small intestine in monkeys and rats, respectively. Segments of approximately 15 and 5 cm around the middle portion of the small intestine were used as middle small intestine, and segments of approximately 15 and 5 cm from the ileocecal This article has not been copyedited and formatted. The final version may differ from this version. for apical (AP) or basal (BL) side, respectively), and gassed with 95% O 2 /5% CO 2 before and during the transport experiment. The midazolam concentration on the donor side was set to be 30, 100 or 300 µM for monkeys, and 10, 30, 100 or 300 µM for rats. At the designated times, a 250 µL aliquot of acceptor side buffer was sampled and replaced with an equal volume of fresh buffer. The experiment was continued for 120 min, after which time the tissue and buffer on the donor side was also collected.
Measurement of midazolam and its metabolites by LC-MS/MS analysis
Midazolam, 1'-OH midazolam and 4-OH midazolam in 100 µL aliquots of plasma were extracted with 10 µL of acetonitrile and 100 µL of internal standard solution (50 ng/mL triazolam in acetonitrile). The mixtures were centrifuged at 3,000 rpm to remove precipitated protein, then 100 µL of supernatant was diluted with 100 µL of 0.01 mol/L ammonium formate (pH 3.0). A This article has not been copyedited and formatted. The final version may differ from this version. min, held at 70% for another 4.25 min, and then brought back to 40% in 0.1 min, followed by re-equilibration for 3.4 min. The total cycle time for one injection was 9 min. MS experiments were conducted on a PE-Sciex API-3000 instrument 
Western blot analysis
The mucosa of the monkey intestine was scraped off, immediately frozen in liquid nitrogen, and stored at -30 °C until use. The scrapings were thawed in the ice-cold buffer containing (mM): 250 sucrose, 10 Tris, 1 EDTA and 
Data analysis
The area under the curve (AUC) and the mean residence time (MRT) were calculated by moment analysis of plasma concentration-time profile with the trapezoidal rule. Pharmacokinetic parameters were calculated in accordance with their definitions. C max and T max are the measured maximum plasma concentration and the time point at which that maximum plasma concentration was observed, respectively.
Transport and metabolic clearances in the Ussing-type chamber were estimated by use of the following equations:
In the AP-to-BL direction, 
In the BL-to-AP direction,
where CL abs , CL met,a-b , X basal and AUC apical are the transport clearance in the AP-to-BL direction, the metabolic clearance in the AP-to-BL direction, the amount of parent drug appearing in the BL compartment, and the area under the parent drug concentration curve in the AP compartment, respectively, while CL sec , CL met,b-a , X apical and AUC basal are the corresponding parameters in the opposite direction. The ΣΜ apical, tissue, basal represents the sum of metabolites (1'-OH and 4-OH midazolam) in the AP, tissue and BL compartments.
The mucosal extraction ratio (ER) was calculated as:
This ER is based on the assumption that ER is affected only by CL abs and CL met,a-b , and can be defined as the contribution of CL met,a-b to the overall elimination clearance (CL abs + CL met,a-b ). Taking Eq (1) ~ (4) into consideration, Eq (5) can be transformed as follows:
Thus, ER as defined above by us is consistent with the definition proposed by
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Since metabolite formation in the Ussing-type chamber was much greater in the AP-to-BL direction than in the BL-to-AP direction, a two-step metabolism model was constructed, assuming that first-pass intestinal removal occurs in association with the uptake phase of midazolam from the apical cell-surface (see Results and Discussion, Fig. 1B ). Accordingly, CL abs , CL met,a-b , CL sec and CL met,b-a are represented by hybrid parameters of plasma membrane permeability, metabolic clearance in intracellular space, and a novel parameter, the fraction of first-pass removal.
CL AT is defined as the membrane permeability of the parent drug (midazolam in the present study) across the apical membrane from outside of the tissue to inside of the tissue (apical-to-tissue). Similarly, CL TA , CL TB and CL BT represent the tissue-to-apical, tissue-to-basal and basal-to-tissue membrane permeabilities, respectively. CL M is metabolic clearance in the intracellular space, and f met is fraction metabolized during the apical uptake.
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In the AP-to-BL direction,
In BL-to-AP direction,
where C tissue,a-b and C tissue,b-a are the parent drug concentration in small intestinal tissue, calculated by assuming that the specific gravity of the tissue is unity, at the end of the experiment after drug administration on the apical and basal sides, respectively. Therefore, all the microscopic parameters (CL AT ~ CL M and f met ) can be directly calculated based on the following equations:
Statistical Analysis
Data are presented as mean ± standard error of the mean (S.E.M.)
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RESULTS
Pharmacokinetics of midazolam after intravenous and oral administration
To understand the pharmacokinetic properties of midazolam in monkeys, dogs and rats, we first measured the plasma concentrations of midazolam after oral and intravenous administration. Plasma concentration-time profiles and the estimated pharmacokinetic parameters are shown in Fig. 2 and Table 1, respectively. Monkeys and rats showed minimal bioavailability (2.1% and 1.1%, respectively), whereas the bioavailability in dogs was 15.1% (Table 1) . Similarly, C max after oral administration was higher in dogs than in monkeys or rats ( Fig. 2 , Table 1 ). The time to maximum concentration (T max ) and the mean absorption time (MAT) were within 1 hr in each species (Table 1 ), indicating that orally administered midazolam was rapidly absorbed. It was also highly distributed in each species, with V dss of 2 ~3 L/kg (Table 1) .
Transport of midazolam across the upper, middle and lower small intestine of monkeys and rats
To directly measure the intestinal transport and metabolism, we used an Ussing-type chamber system to examine vectorial transport across upper, middle and lower small intestinal segments, with 30 µM midazolam in the donor side chamber. One of the advantages of using an Ussing-type chamber for analyzing intestinal drug transport is the ease of assessment of bi-directional transport
across intestinal tissues (AP-to-BL and BL-to-AP). Transport clearances (CL abs
This article has not been copyedited and formatted. The final version may differ from this version. and CL sec ) and metabolic clearances (CL met,a-b and CL met,b-a ) were calculated from the AP-to-BL and BL-to-AP transport data for each segment of the small intestine.
Metabolic clearance was much higher than the transport clearance in all segments in monkeys, whereas in rats, transport clearance was higher than the metabolic clearance in all the segments (Fig. 3A, 3B, 3D, 3E ). There was also clear species difference between monkeys and rats in the absolute values of metabolic clearance (Fig. 3B, 3E ). Extraction ratio (ER) calculated from Eq (5),
was much higher in all segments in monkeys than in rats (Fig. 3C, 3F ). These results suggest that there is a predominant first-pass effect in the small intestine of monkeys (Fig. 3C) , in contrast to a small intestinal first-pass effect in rats (Fig.   3F ). It is noteworthy that metabolic clearance and ER in monkey upper small intestine were higher in the AP-to-BL direction than in the BL-to-AP direction (Fig.   3B, 3C ).
Concentration dependence of intestinal transport clearance of midazolam in monkeys and rats
To investigate nonlinearity in the intestinal absorption of midazolam, the concentration dependence of CL abs was examined in the middle small intestine of both species. CL abs tended to increase with increasing concentrations of midazolam in monkeys, whereas it tended to decrease with increasing concentrations of midazolam in rats (Fig. 4A, 4B ), suggesting that different mechanism(s) are involved in the nonlinear absorption of midazolam in the two species. Similar increase and decrease with increasing midazolam concentration were also observed for CL seq in monkeys and rats, respectively (Fig. 4C, 4D ). On the other hand, significant saturation of CL met,a-b and CL met,b-a was observed in monkey and rat middle small intestine (Fig. 4E, 4F , 4G, 4H). In a nonlinear absorption study with monkey upper small intestine, CL met,a-b at 300 µM midazolam was much lower than that at 30 µM midazolam and similar to CL met,b-a (CL met,a-b and CL met,b-a at 300 µM were 3.23 ± 0.54 and 2.06 ± 0.41 10 -6 cm/s, respectively). This is in contrast to the clear difference between CL met,a-b and CL met,b-a at 30 µM midazolam in monkey upper small intestine (Fig. 3B ).
Excretion of midazolam metabolites
We next measured the appearance of metabolites on the apical and basal sides, and in intestinal tissue (Table 2) . When midazolam was added to apical side, larger amounts of metabolites appeared on the apical side for both monkey and rat small intestinal segments (Table 2) . On the other hand, when midazolam was added to the basal side, the appearance of metabolites on the basal side was similar to or higher than that on the apical side, especially at lower substrate concentration (Table 2) . Addition of higher concentrations of midazolam to the basal side tended to decrease the appearance of metabolites on the basal side, but to increase that on the apical side (Table 2) , suggesting the involvement of saturable efflux system(s) for metabolites in the basal membrane.
Model-dependent analysis
To understand in more detail the intestinal transport and metabolism of midazolam, we attempted to estimate intrinsic parameters that directly represent membrane permeability and intracellular metabolism. We employed a simple model that included only apical-to-tissue permeability (CL AT ), and tissue-to-apical cm/sec)), whereas in monkeys, the CL M values obtained from AP-to-BL and BL-to-AP transport studies at the same concentration of midazolam were 22.6 ± 5.5 and 1.40 ± 0.61 in upper small intestine, 18.1 ± 3.9 and 7.28 ± 1.99 in middle small intestine, and 18.3 ± 4.6 and 11.1 ± 5.6 in lower small intestine, respectively.
Thus, disposition of midazolam in monkey small intestine is more complicated than that in rats.
Therefore, it seems that a novel kinetic model is necessary to explain the overall data in rats and monkeys. Since the CYP3A protein distribution has been reported to be biased toward the apical membrane side, at least in rat intestinal epithelial cells (Kolars et al., 1992a) , we next considered a novel, two-step metabolism model (Fig. 1B) , in which metabolism occurs heterogeneously.
Parameters obtained with this model are listed in Table 3 . The CL M was saturable, especially in monkeys, and, in addition,, CL AT and CL BT were also saturable at higher substrate concentrations in rats. The f met value, which represents the fraction metabolized during apical uptake, was higher in the upper small intestine than in other segments and tended to decrease at higher substrate concentrations in all segments of monkeys (Table 3) . On the other hand, the f met value was close to zero in all segments of rats ( Table 3 ), suggesting that metabolism of midazolam is heterogeneous in monkeys, but not in rats. The CL AT in the lower small intestine was higher than that in the upper segments of the intestine in both monkeys and rats (Table 3) .
CYP3A expression in monkey and rat small intestine
To investigate the correlation between metabolic activity and expression of CYP3A protein in the small intestine, Western blot analysis was performed. In this experiment, anti-CYP3A4 and anti-CYP3A2 antibodies were employed to detect immunoreactive proteins in monkeys and rats, respectively, since it has been reported that immunochemical reactivity to anti-CYP3A antibody is similar in monkeys and humans (Shimada et al., 1997) , and that CYP3A2 antibody cross-reacts with other protein(s) that probably belong to the CYP3A family in rats (Aiba et al., 2005) . As shown in Fig. 5 , CYP3A proteins were detected in all intestinal segments of both monkeys and rats. Further, CYP3A expression tended to be higher in the upper small intestine than in other segments in both monkeys and rats (Fig. 5 ).
DISCUSSION
Monkeys are sometimes used in preclinical studies because they are expected to show similar pharmacokinetic characteristics to humans. Indeed, Ward and Smith (2004) reported that values of total body clearance normalized to hepatic blood flow in humans were better correlated to those in monkeys than to those in rats or dogs, while Chiou and Buehler (2002) noted that hepatic clearance per body weight was higher in monkeys than in humans. However, in the case of oral administration of drugs, monkeys often show lower bioavailability than humans (Sietsema, 1989; Chiou and Buehler, 2002; Ward et al., 2005) . This could be explained by insufficient intestinal availability in monkeys. To clarify the mechanism of this interspecies difference of oral bioavailability, we chose midazolam as a model drug to analyze intestinal metabolism in monkeys in the present study, since it is useful as a probe for CYP3A, which is functionally expressed in the small intestine, and it also shows a marked interspecies difference in oral bioavailability between human and animals (Sakuda et al., 2006) . We confirmed that the bioavailability of midazolam was at most 2% in both monkeys and rats (Table 1) . However, we observed extensive intestinal metabolism of midazolam (ER value close to unity) in monkeys, but not in rats (Fig. 3) , suggesting that oral bioavailability is affected by intestinal first-pass metabolism in monkeys, whereas in rats, bioavailability of midazolam is mainly determined by hepatic metabolism.
In Ussing chamber experiments, we found that exposure of the apical Fig. 3 ) in monkeys and rats. The small intestine in monkeys showed much higher CL met,a-b than CL abs , whereas CL abs was much larger than CL met,a-b in rats, resulting in a species difference of ER between monkeys and rats (Fig. 3) . piperazine-Phe-homoPhe-vinylsulfone phenyl), which is a substrate of P-gp and CYP3A, between the AP-to-BL and BL-to-AP directions was caused by a slowing of absorption mediated by P-gp. They also reported that midazolam, which is not transported by P-gp, exhibited a similar ER difference between the AP-to-BL and BL-to-AP directions, and speculated that in this case the ER difference might be due to a difference in the times required for the intracellular midazolam concentration to reach a steady state .
Although these studies were performed in transfectant cell lines in vitro, we have shown that such ER differences exist in upper small intestine freshly isolated from monkeys in the present study (Fig. 3) . The mechanism(s) of this ER difference has not yet been clarified in detail, but it is noteworthy that the appearance of midazolam metabolites also depended on the direction of transport, with metabolites being found preferentially on the apical side after addition of midazolam to the apical side, but not to the basal side (Table 2 ). This observation can be explained by asymmetric localization of metabolic activity in the small intestine. CYP3A is known to show inhomogeneous subcellular localization in intestinal epithelial cells, and is more abundant in the vicinity of the apical membrane than the basal membrane, at least in rats (Kolars et al., 1992a) .
Consequently, we speculate that intestinal metabolic enzymes tend to rapidly metabolize drugs absorbed across the apical membrane, compared to those entering from the basal membrane, thereby providing a barrier against entry of Cummins et al., 2002) . This finding is consistent with our hypothesis that midazolam absorbed from intestinal lumen is rapidly metabolized.
Based on the idea that metabolism of midazolam occurs faster when it is taken up from the apical side, we constructed a novel two-step metabolism model (Fig. 1B) . Although the validity of this model should be confirmed by further analyses, this model can well describe the directional metabolism, assuming a single compartment, even though it requires only one additional parameter (f met ) compared with a single-compartment model, together with membrane permeability (CL AT -CL BT ) and intracellular metabolism (CL M ). Based on this model, ER abs defined by Eq (4) can be described as follows:
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Midazolam is classified into BCS class I, with high membrane permeability (Wu and Benet, 2005) . Nevertheless, saturable transport of midazolam was observed in apical (CL AT ) and basal (CL BT ) uptake in rat middle and lower small intestine (Table 3) , and this was compatible with the saturation of CL abs and CL sec in rat middle small intestine (Fig. 4B, 4D ) and lower small intestine (the values of CL abs and CL sec at 30 µM midazolam in the donor side chamber were 28.0 ± 8.1 and 26.2 ± 5.6, and those at 300 µM midazolam were 10.6 ± 2.8 and 12.7 ± 2.0, respectively). Apical uptake (CL AT ) of midazolam also decreased when a concentration of 300 µM was given in the upper small intestine of monkeys (Table   3 ). Nevertheless, CL abs increased as the midazolam concentration was increased (CL abs at 30 µM midazolam in the donor side chamber was 0.454 ± 0.093 and CL abs at 300 µM was 0.839 ± 0.172). Regarding the saturation of f met (Table 3) (Table 3) , contributing to the enhancement of CL abs .
Although we have observed saturable intestinal transport of azasetron, which is highly soluble and permeable (Tamai et al., 1997) , involvement of influx/efflux transporter(s) in gastrointestinal absorption of BCS class I drugs is believed to be rare (Wu and Benet, 2005) . The present report is the first to describe saturable absorption process for midazolam. Further analyses will be needed to investigate whether a carrier-mediated transport system(s) is involved in the intestinal absorption of midazolam.
Model-dependent analysis of the intestinal absorption of midazolam in monkeys revealed nonlinear behavior of several parameters representing metabolism (CL M and f met , Table 3 ). The K m values of human CYP3A4 for 1'-and 4-OH midazolam formation were 1.56 and 38.0 µM, respectively (Ghosal et al., 1996) . Although the intracellular unbound concentration of midazolam is unknown, saturation could occur at relatively high midazolam concentrations.
Actually, CL M in each intestinal segment of monkeys was decreased at higher concentrations in the donor side buffer (Table 3) , indicating saturation of intracellular metabolism. On the other hand, the f met values were similar at lower (30 µM) and higher (300 µM) concentrations in the donor side medium for monkey middle small intestine (Table 3) . Therefore, the characteristics of the enzyme(s) contributing to CL M and f met could be different in monkey middle small intestine. The f met in monkeys was 0.4 ~ 0.9 at the lowest midazolam concentration, while in rats, f met was close to zero in all the segments (Table 3) , indicating that rapid and substantial metabolism of midazolam during apical uptake in the small intestine occurs in monkeys, but not in rats. On the other hand, the CL M was not so different between monkeys and rats, especially in the upper segments of the intestine (Table 3) . Thus, the species difference in metabolism of midazolam arises mainly during the apical uptake phase (f met ). It is not surprising that the f met has not been taken into consideration in estimating intestinal drug absorption, since f met is monkey-specific (Table 3) , and rats, which exhibit minimal f met at least for midazolam, are mainly used in preclinical studies. It is generally considered that molecules responsible for uptake and metabolism (e.g., transporters and CYP enzymes) are separately localized in cells (e.g., in
cell-surface membranes and microsomes), so the concept of drug metabolism during uptake from the apical cell-surface may seem to be unphysiological.
However, the possible existence of monkey-specific molecules has not yet been excluded. Further, the "directional metabolism" observed in the current study can be well explained by this model. Therefore, we believe that it is reasonable to conclude that metabolic events are at least tightly linked with uptake from the apical cell surface. In other words, we suggest that first-pass intestinal removal is functionally closely associated with apical uptake in cynomolgus monkeys, even though it is still unclear whether f met and CL M are physiologically related to each other, and whether the molecules responsible for f met and CL M are different or not.
Further studies are necessary to investigate the molecule(s) responsible for f met and CL M .
This article has not been copyedited and formatted. The final version may differ from this version. The CYP3A immunoreactivity was higher in the upper small intestine than in other segments of both monkeys and rats (Fig. 5) . This may be compatible with the segmental difference in f met , which was higher in the upper small intestine than in other segments of both species, although its absolute value was quite small in rats (Table 3) . However, involvement of other metabolic enzyme(s) in the oxidation of midazolam can not be ruled out. It is important to realize that oral bioavailability can be affected by many factors, including regional differences in activities of intestinal metabolic enzymes, and differences in the residence time of drug molecules in different intestinal segments.
In conclusion, our findings with an Ussing-type chamber system indicate that the minimal oral bioavailability of midazolam in cynomolgus monkeys is a consequence of rapid and extensive intestinal metabolism that is associated with the uptake of midazolam across the apical membrane cell-surface. Since midazolam is a typical substrate of CYP3A, many other CYP3A substrate drugs could also be extensively metabolized in monkey intestine and thus show low bioavailability. On the other hand, saturable transport mechanism(s) are involved in the uptake of midazolam into intestinal tissues especially in rats. These findings will be helpful for evaluating the results of preclinical studies and predicting their relevance to drug absorption in humans.
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